Objective To detect the effect of Hui-sheng oral liquid on the expression of Interleukin-6 and Interleukin-18 of patients with advanced non-small-cell lung cancer (NSCLC) and to investigate its possible anti-tumor mechanism. Methods Eighty-two patients with advanced NSCLC were recruited and randomly divided into two groups: the combined chemotherapy group (NP chemotherapy and hui-sheng oral liquid, n=42) and the single chemotherapy (only NP chemotherapy, n=40). The effective rates were evaluated after two cycles’ treatment. The expression of serum IL-6 and IL-18 were detected by the enzyme linked immunoassay (ELISA) before and after two cycles’ treatment. Results The total effective rate was 38.1％ (16/42) for the combined chemotherapy group, and 35.0％ (14/40) for the single chemotherapy group; there was no significant difference (P=0.697) between the two groups. No difference was found in the expression of IL-6 and IL-18 before and after treatment in the single chemotherapy group (P=0.623). While compared with before treatment, the expression of both IL-6 and IL-18 were significantly up-regulated after treatment in combined chemotherapy group (P=0.005). Conclusion The adjuvant treatment with hui-sheng oral liquid could increase the expression of IL-6 and IL-18 of patients with NSCLC and enhance their immunizing power.